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Introduction
Down syndrome (DS) is one of the most common birth
defects in the United States with resulting in an estimated birth prevalence of 12.6 per 10 000 live births.1
DS is characterized by a heterogenous phenotype that
results from a dosage imbalance of genes on human
chromosome 21.2 Due to the heterogenous phenotype,
broad presentation of presenting symptoms, and complex needs of the child with DS, the American Academy
of Pediatrics (AAP) published a clinical report for the
health supervision of children with DS.3 The report discusses age-appropriate guidance on when to screen for
specific conditions, when to refer to specialty care for
evaluation, and anticipatory guidance for families as
their child with DS ages.
Inflammatory arthritis in children with DS was first
described in 1984 and was termed Down syndrome
arthropathy,4 however, the term Down syndrome-associated arthritis (DA) has been recommended to better
describe the inflammatory nature of the disease.5 Studies
have shown that DA is under-recognized with a delay in
diagnosis.6 Most patients present with polyarticular (5
or more joints with arthritis), rheumatoid factor (RF),
and anti-nuclear antibody (ANA) negative disease.6
There are reports that DA is more prevalent than juvenile idiopathic arthritis (JIA),5,7 which is the most common pediatric rheumatologic disease.8 Additionally, DA
appears more aggressive than JIA with more bone and
joint damage at presentation, and despite aggressive
therapy with disease modifying antirheumatic drugs
(DMARDs) and biologic therapy, disease burden is
higher for those with DA compared to JIA.9 Despite this
the American Academy of Pediatrics does not mention
arthritis or screening for arthritis in the clinical report
for health supervision of children with DS.
In a national survey of Down syndrome clinic providers, 77% responded that they were aware of the risk
for inflammatory arthritis in DS, however, less than half

educated families about the risk, which is likely due to
the lack of guidance around screening and evaluation for
DA.10 The uncertainty and lack of guidance in screening
for DA is a gap in the medial literature. Our objective
was to develop and pilot a brief musculoskeletal screen
for DA and our secondary objective was to provide education to families about DA.

Methods and Materials
As part of a cross-sectional study, a convenience sample
of 91 children with Down syndrome were recruited at
routine clinical care visits at 1 tertiary care center, in
sequential order over a 6-month period, provided eligibility criteria were met. Patients were eligible if they
were between the age of 1 to 17 years of age, and confirmed Down syndrome, and seen in the Down Syndrome
Clinic. To confirm diagnosis karyotypes were reviewed,
but not collected for report as phenotype is similar
despite differences in karyotype.11 Patients and families
were asked 2 brief musculoskeletal screening questions.
(1) “Over the past 3 months, have you noticed any joint
swelling in your child?” and (2) “Over the past 3 months,
have you noticed any morning stiffness in your child?”
These questions were chosen specifically to be brief,
but also because reports suggest that >75% of patients
reported morning stiffness and joint swelling at diagnosis of arthritis.6,7 If the screening questionnaire was
positive (affirmative answer for 1 or both questions),
the medical care provider would contact a pediatric
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Figure 1. Brief musculoskeletal screen flow diagram.

rheumatology co-investigator to complete a musculoskeletal joint exam to determine if arthritis was present.
Additionally, all positive screens had an erythrocyte
sedimentation rate (ESR) obtained at the visit as previous studies suggest an elevated ESR is present in the
majority of those with DA.6,7 Imaging studies were
obtained if warranted by the pediatric rheumatologist
conducting the musculoskeletal exam (Figure 1). If
arthritis was present the patient would be treated with
standard of care for pediatric inflammatory arthritis. If
arthritis was not present, follow-up, if necessary, was
determined by the pediatric rheumatologist.
Upon discharge from the DS clinic visit, evidencebased education about DA was provided to all families. A smart form was created to guide medical
providers through the education and document completion. This included statements about increased risk
of arthritis in children with DS, and signs and symptoms of arthritis (Figure 2). About 1 week after the
study visit families completed a phone interview to
assess the education and brief musculoskeletal screening at their visit to determine feasibility and implementation in the future. The follow-up questionnaire
had multiple choice questions and a place for respondents to fill-in any additional responses or comments.
Some questions were asked on a 5-point Likert scale.
Gender, age, and ethnicity were collected as demographic information.
The results were analyzed by descriptive statistics
and performed using IBM SPSS Statistics version 24.

Ethical Approval and Informed
Consent
Written informed consent was obtained from all legal
guardians and there was a waiver of assent for the
patients. This work was conducted in accordance with
the Declaration of Helsinki. Institutional review board
approval was obtained from Children’s Mercy Kansas
City (IRB ID: 16060435).

Results
Of the 91 patients with Down syndrome who were
screened, 48 (53%) were male with a mean age of
7.2 years (SD 5.0). Most were Caucasian (77%) followed
by African American (11%), and Hispanic (9%). There
were 4 positive screens (4%), all (100%) had a normal
ESR, and all had imaging studies completed. About 2
had x-rays, which were normal, and 2 had ultrasounds, 1
of which was normal and 1 that was abnormal and consistent with arthritis.
All 91 completed the follow-up questionnaire with
100% (91/91) saying they were comfortable with their
child being screened for arthritis in clinic. When asked
how they would rate the ease of the screening on a
5-point Likert scale (Extremely easy to Very difficult),
60% (54/91) rated it extremely easy while 40% (37/91)
rated it very easy. All 91 reported the musculoskeletal
screen was an appropriate use of clinic time at their
clinical visit, and they would like their child’s primary

Jones et al

3

Figure 2. Brief educational information smart form about inflammatory arthritis in Down syndrome that was given to
families. This form is fully completed by medical staff to document education and discussion of arthritis with the family.

provider to continue to screen for arthritis at future clinical visits. When parents were asked if they knew their
child was at increased risk to develop inflammatory
arthritis, 86% (78/91) reported they were unaware of the
risk prior to their clinic appointment.

Discussion
Down syndrome-associated arthritis (DA) is a significant cause of musculoskeletal morbidity in children with
Down syndrome (DS), and despite the increased risk of
DA in patients with DS there is lack of awareness and no
formal guidance on screening or surveillance of DA. In
the most recent version of the AAP Health Supervision
of Children with Down Syndrome,3 there is no mention of screening or surveillance for arthritis. Other
challenges for children with DS are the risk for developmental delays, high pain tolerance, compromised
communication skills and noninflammatory musculoskeletal conditions such as ligament laxity and pes
planus,12,13 which may mislead providers and delay

diagnosis. As there is no guidance or recommendations
for screening for DA, we developed and piloted a brief
musculoskeletal screen and provided education that was
feasible for families.
Our brief musculoskeletal screen identified 4 patients
with musculoskeletal symptoms concerning for inflammatory arthritis, with 1 was ultimately diagnosed with
DA, which gives an incidence of 1% for this study. The
current prevalence of DA has been reported at 1% to
2%,5,7 which is like other conditions associated with
DS such as atlantoaxial instability, leukemia, and
Hirschsprung disease, all of which are mentioned in the
clinical report for health supervision of children with
DS. The exemption of DA from the health supervision
and anticipatory guidance education for children with
DS is a contributor to the delay in diagnosis of DA,6 and
likely why the parents in this study are mostly unaware
of the risk for inflammatory arthritis in their child. We
propose providing education and anticipatory guidance
to families about the risk of DA to increase awareness.
The parents surveyed did report interest in regular
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screening for DA, and the increased awareness may
lead to earlier screening, diagnosis, and treatment,
which could prevent worse outcomes.
As part of the brief musculoskeletal screen, all positive screens had an ESR obtained to evaluate for systemic inflammation. This was chosen because earlier
reports of DA show that many with DA (56%-100%) had
an elevated ESR at diagnosis of arthritis,6,7,14 however,
none of the patients in this study had an abnormal ESR.
This is more consistent with a recent report that shows
that at diagnosis of DA almost half (44%) have normal
laboratory tests (CBC, CRP, ESR, RF, ANA), and only
17% had an abnormal CRP and ESR.9 The difference
between the studies is attributed to earlier diagnosis and
increased awareness that is supported by a shorter average time to diagnosis of DA (8.3 months) compared to
older studies that report a 19-month average time to diagnosis. This indicates that laboratory tests may be less
helpful in a screening tool for evaluation of DA.
All positive screens in this study did have imaging
obtained. This is likely due to a recent study that showed
that children with DA have more radiographic changes
consistent with arthritis at diagnosis compared to those
with JIA (38% vs 22%).9 However, with imaging there
is a discrepancy in utilization of imaging modalities in
screening for DA as imaging is not frequently utilized
by Down Syndrome Clinic providers in their evaluation
for DA.10 While the reason for this is unclear, it may be
due to limiting radiation exposure in individuals with
higher prevalence of malignancy.15 In comparison,
x-rays are the most used imaging modality for pediatric
rheumatologists to aid in evaluation of DA,16 which is
likely due to their accessibility and reproducibility.
However, x-rays are not sensitive enough to reveal subtle or early arthritis, and ultrasound, which is the second
most used imaging modality of pediatric rheumatologist
in evaluating DA,16 has the capabilities to pick up more
subtle disease and tendon changes. Ultrasound does
have limitations, which includes that it is operator
dependent and may not be as reproducible from 1 technician to another17 or as readily available depending on
clinical setting.
Our study has several limitations, which includes the
limited number of questions on the musculoskeletal
screen, which should be broadened to improve sensitivity, however, we wanted the questions to be focused and
brief so to be minimally invasive to clinic flow and easy
to administer. We also understand that having a pediatric
rheumatologist perform a physical exam for a positive
musculoskeletal screen is not feasible at all institutions
and a standardized approach for musculoskeletal exam
specific for those with DS that could be easily administered by primary care providers should be developed for
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DA. Another limitation was the imaging discretion for
joints that were suspicious for arthritis by the pediatric
rheumatologist, which was inconsistent as x-rays and
ultrasound were used instead of clear guidance on imaging approach and modality. The reason this was not standardized was based on the clinical situation of the
patients and their family as some families travel and
have long appointments, and ultrasounds could not be
coordinated on the same day, so x-rays were used as a
convenience to the family. However, ultrasound may be
a better option for an imaging tool for screening in DS
due to the lack of radiation and increased musculoskeletal detail obtained.
Down syndrome-associated arthritis (DA) remains a
significant source of morbidity for children with Down
syndrome (DS), there are currently no recommendations
to help primary providers screen for this condition.
Based on this study we propose implementation of
global evidence-based education about risk of DA as
part of regular anticipatory guidance given to families
that have children with DS. Additionally, implementation of a brief musculoskeletal screen as part of a health
screening for DS like the one in this study could be
administered by providers at interval clinic visits to
identify cases of inflammatory arthritis earlier. We propose focused questions about musculoskeletal health,
focused musculoskeletal exam, with laboratory tests and
imaging options as part of the musculoskeletal screen.
Further studies are needed to improve the educational
materials, the musculoskeletal screen and implement it
on a larger scale.
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